Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Trial of Pembrolizumab Plus Chemoradiotherapy in Participants With Unresectable Gastroesophageal Cancer

NCT04522336 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT04522336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04522336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Trial of Pembrolizumab Plus Chemoradiotherapy in Participants With Unresectable Gastroesophageal Cancer
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
September 16, 2020
Completion date
August 7, 2026
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iv gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iva gastroesophageal junction adenocarcinoma ajcc v8, clinical stage ivb gastroesophageal junction adenocarcinoma ajcc v8, localized gastroesophageal junction adenocarcinoma, locally advanced gastroesophageal junction adenocarcinoma, pathologic stage iii gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiia gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiib gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iv gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iva gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage ivb gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iii gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiia gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiib gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iv gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iva gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage ivb gastroesophageal junction adenocarcinoma ajcc v8, unresectable gastroesophageal junction adenocarcinoma